Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

MC10, UCB collaborate to assess patient monitoring in Parkinson’s disease

MC10, the company pioneering conformal, body-worn computing systems, has announced the successful completion of their innovative collaboration with global biopharmaceutical company UCB, investigating the application of wearable, ambulatory sensors in providing clinical grade Parkinson's Disease data.

This study is the first and most comprehensive of its kind between a wearable technology company and a major pharmaceutical company.

The results of the study, targeted for scientific publication, represent the culmination of over two and a half years of partnership between UCB and MC10.

“MC10’s core mission of leveraging our unique technology to improve the understanding of human health and wellness is well aligned to UCB’s commitment to patient-centered care,” commented Scott Pomerantz, MC10’s Chief Executive Officer.

“Our collaboration with UCB has allowed us to grow as a company by better understanding the needs of patients and the pharmaceutical industry’s efforts and approaches to meeting their needs.”

The study assessed the feasibility of monitoring Parkinson’s Disease patients in clinic and home settings while wearing sensors built with MC10’s unique epidermal electronics platform. In addition to data recorded from the wearable sensors, researchers collected neurological assessments from trained clinicians and patient reported outcomes.

“Completion of this study is testament to UCB’s mission to foster innovation to help the millions of people living with chronic neurodegenerative diseases. UCB is focused on improving understanding about patent experiences, and evolving these insights to improve the management of neurological conditions – providing patients with better control and allowing them to improve treatment outcomes,” explained Erik Janssen, Vice President Global New Patient Solutions, Neurology at UCB.

“In combination with our own clinical and development teams, MC10’s innovative solutions shaped the study at both a hardware and software level. We hope these results, once disseminated, will influence the broader community’s thinking about the place of novel technologies in patient care.”

The study results are being prepared by MC10 and UCB for presentation and publication in 2017.

UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.